Analyst Mohit Bansal opines AbbVie might favour purchasing C...
Analyst Mohit Bansal opines AbbVie might favour purchasing Cerevel due to its perceived clean IP and daily dosing for its principal schizophrenia medication. He anticipates potential benefit from peak adjustments in sales surpassing $3B.
AbbVie – Cerevel M&A Deal Lifts Reviva, Karuna
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3168Followers
0Following
7918Visitors
Follow